Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$75.95M
1.35M shares · 0.0% of portfolio
Royalty Pharma plc
Royalty Pharma plc (RPRX) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in New York, United States and has 100 employees. The company is worth $36.84B and trades at 33.0x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $2.38B in fiscal 2025, up 5.1% from the year before. Net income was $770.95M. The share price is within 3% of its 52-week high. It pays a dividend yielding 1.47%. 8 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Baillie Gifford (Baillie Gifford & Co), at $561.57M. In that quarter, 4 of them opened or added to the position and 3 reduced it. Over the last 30 days, company insiders sold $474.41K of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +53.3% over 5Y.
today you would have $1,733.26▲ +73.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $38.64 | $25.51 | $28.09 | $39.52 | $39.85 | $50.05 | |
| P/E | 21.7x | 21.7x | 13.4x | 11.1x | 395.2x | 26.7x | 37.9x |
| P/S | 7.5x | 9.2x | 6.7x | 7.2x | 7.7x | 7.2x | 8.9x |
| P/B | 1.7x | 2.2x | 1.5x |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 6.2% a year plus a 1.5% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 21.7 across this company’s own years on record.
Cash flow growing 6.2% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BIIBBiogen Inc | $253.84 | 45.1x | 2.0x | 0.00% | 4.58% | $37.51B |
| RMDResmed Inc | $253.06 | 23.6x | 5.5x | 1.04% | 24.27% | $35.59B |
| CNCCentene Corp | $71.24 | — | 1.6x | 0.00% | -20.36% | $35.19B |
| ALCAlcon Inc | $70.63 | 51.2x |
| 1.7x |
| 1.8x |
| 1.6x |
| 1.9x |
| EPS | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 | $1.32 |
| Dividend yield | 2.10% | 2.28% | 3.29% | 2.85% | 1.92% | 1.71% | 0.60% |
| Payout | 44.81% | 49.44% | 43.98% | 31.62% | 760.00% | 45.64% | 22.73% |
| Profit margin | 35.18% | 32.42% | 37.95% | 48.20% | 1.91% | 27.07% | 45.94% |
| ROE | 8.12% | 7.94% | 8.31% | 11.25% | 0.45% | 6.05% | 9.85% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
-37.0% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 1.6x |
| 0.51% |
| 2.94% |
| $34.14B |
| ZTSZoetis Inc. | $82.00 | 13.5x | 10.8x | 2.59% | 64.91% | $33.88B |
| MTDMettler Toledo International Inc/ | $1,684.64 | 38.0x | 2632.3x | 0.00% | — | $33.75B |
